A*STAR Singapore Immunology Network (A*STAR SIgN)

Researchers unravel a complex inflammatory pathway involved in severe COVID-19 infection and identify a therapeutic mechanism to reverse it.

A new analytical platform reveals signature changes in immune cells of the brain during aging and neurodegenerative conditions such as Alzheimer’s disease.

An analysis of cellular immune responses reveals that mixing COVID-19 vaccines and boosters may offer enhanced protection for at-risk populations.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

Booster shots with COVID-19 mRNA outperformed inactivated virus by eliciting stronger antibody responses to the Omicron variant.

Drug-resistant malarial parasites form flower-like structures to shield themselves from attack by antimalarial drugs and the immune system.

A*STAR scientists decipher how a stem cell-based treatment stops the uncontrolled inflammation associated with severe COVID-19 cases.

A T cell therapy innovation may offer new hope for acute myeloid leukemia patients who relapse after conventional treatment.

Using a new genome analysis technology, A*STAR scientists discover never-before-seen immune responses in tuberculosis infections.

More evidence emerges that fatty foods change skin composition, creating the perfect conditions for acne flare-ups.

A profile of the immune responses from Singaporean patients recovered from COVID-19 has revealed an urgent need to update vaccines against new viral variants.

A deletion in the genome of SARS-CoV-2 variants makes resulting infections milder and could also be a target for future COVID-19 treatments.